Zobrazeno 1 - 10
of 208
pro vyhledávání: '"Juan Carlos Hernández-Boluda"'
Autor:
Valentín García-Gutiérrez, María Teresa Gómez-Casares, Blanca Xicoy, Felipe Casado-Montero, Guillermo Orti, Pilar Giraldo, Juan Carlos Hernández-Boluda
Publikováno v:
Frontiers in Oncology, Vol 14 (2024)
Chronic myeloid leukemia (CML), characterized by the presence of the BCR::ABL1 fusion gene, has undergone a transformative shift with the introduction of tyrosine kinase inhibitors (TKIs). The current availability of six different TKIs (imatinib, das
Externí odkaz:
https://doaj.org/article/171f72ea8b64423490f5a5a108df9b36
Autor:
Rosa Ayala, Rafael Alonso Fernández, Valentín García‐Gutiérrez, Alberto Alvarez‐Larrán, Santiago Osorio, Jose M. Sánchez‐Pina, Gonzalo Carreño‐Tarragona, Noemi Álvarez, María Teresa Gómez‐Casares, Antonia Duran, Julian Gorrochategi, Juan Carlos Hernández‐Boluda, Joaquín Martínez‐López
Publikováno v:
eJHaem, Vol 4, Iss 2, Pp 401-409 (2023)
Abstract This phase Ib, non‐randomized, open‐label study evaluates the safety and tolerability of ruxolitinib in combination with nilotinib and prednisone in patients with naïve or ruxolitinib‐resistant myelofibrosis (MF). A total of 15 patien
Externí odkaz:
https://doaj.org/article/4673dbbcf429471da51236926d331917
Autor:
Marcos Rivada, Cristina Soler, Rafael Hernani, Ana Benzaquén, Montse Gómez, Rosa Goterris, Ignacio Arroyo, Ángela Cámara, Ariadna Pérez, José Luis Piñana, Juan Carlos Hernández-Boluda, Paula Amat, Irene Pastor, María José Remigia, Blanca Ferrer, María José Terol, Carlos Solano
Publikováno v:
HemaSphere, Vol 7, p e3405129 (2023)
Externí odkaz:
https://doaj.org/article/d17c00f1e67244ab81ae854c4457e094
Autor:
Alberto Alvarez-Larrán, Beatriz Cuevas, Patricia Velez, Soledad Noya, Gonzalo Caballero-Navarro, Francisca Ferrer-Marín, Sara Carbonell, Manuel Pérez-Encinas, María Teresa Gómez-Casares, Raúl Pérez-López, Elena Magro, Ana Moretó, Irene Pastor-Galán, Anna Angona, María Isabel Mata-Vázquez, Lucía Guerrero-Fernández, José María Guerra, Gonzalo Carreño-Tarragona, Laura Fox, Ilda Murillo, Valentín García-Gutiérrez, Elvira Mora, Ruth Stuckey, Eduardo Arellano-Rodrigo, Juan Carlos Hernández-Boluda, Arturo Pereira, On behalf of the MPN Spanish Group (GEMFIN)
Publikováno v:
HemaSphere, Vol 7, Iss 8, p e936 (2023)
The International Prognostic Score of thrombosis in Essential Thrombocythemia (IPSET-thrombosis) and its revised version have been proposed to guide thrombosis prevention strategies. We evaluated both classifications to prognosticate thrombosis in 13
Externí odkaz:
https://doaj.org/article/f2ee380a4d90401d8358db4f7ee45651
Autor:
Sílvia Marcé, Aleix Méndez, Blanca Xicoy, Natalia Estrada, Marta Cabezón, Antonella Luciana Sturla, Miriam Ratia García, Anna Angona, Paula Amat, Silvia Escribano Serrat, Emilia Scalzulli, Mireia Morgades, Alicia Senín, Juan Carlos Hernández-Boluda, Francisca Ferrer-Marín, Eduardo Anguita, Montserrat Cortés, Esther Plensa, Massimo Breccia, Valentín García-Gutierrez, Lurdes Zamora
Publikováno v:
Journal of Clinical Medicine, Vol 13, Iss 3, p 779 (2024)
e13a2 and e14a2 are the most frequent transcript types of the BCR::ABL1 fusion gene in chronic myeloid leukemia (CML). The current goal with tyrosine kinase inhibitors (TKI) is to achieve sustained deep molecular response (DMR) in order to discontinu
Externí odkaz:
https://doaj.org/article/0e138f26b5484f789363573b581bfa3b
Autor:
Ignacio Torres, Dixie Huntley, Mar Tormo, Marisa Calabuig, Juan Carlos Hernández-Boluda, María José Terol, Carlos Carretero, Paula de Michelena, Ariadna Pérez, José Luis Piñana, Javier Colomina, Carlos Solano, David Navarro
Publikováno v:
BMC Infectious Diseases, Vol 22, Iss 1, Pp 1-10 (2022)
Abstract Background To investigate the multi-drug resistant bacteria (MDRB) colonization rate in hematological patients hospitalized for any cause using a multi-body-site surveillance approach, and determine the extent to which this screening strateg
Externí odkaz:
https://doaj.org/article/a0a0c778dcda44e09197459df815c055
Autor:
Adrián Mosquera-Orgueira, Manuel Pérez-Encinas, Alberto Hernández-Sánchez, Teresa González-Martínez, Eduardo Arellano-Rodrigo, Javier Martínez-Elicegui, Ángela Villaverde-Ramiro, José-María Raya, Rosa Ayala, Francisca Ferrer-Marín, María-Laura Fox, Patricia Velez, Elvira Mora, Blanca Xicoy, María-Isabel Mata-Vázquez, María García-Fortes, Anna Angona, Beatriz Cuevas, María-Alicia Senín, Angel Ramírez-Payer, María-José Ramírez, Raúl Pérez-López, Sonia González de Villambrosía, Clara Martínez-Valverde, María-Teresa Gómez-Casares, Carmen García-Hernández, Mercedes Gasior, Beatriz Bellosillo, Juan-Luis Steegmann, Alberto Álvarez-Larrán, Jesús María Hernández-Rivas, Juan Carlos Hernández-Boluda, on behalf of the Spanish MPN Group (GEMFIN).
Publikováno v:
HemaSphere, Vol 7, Iss 1, p e818 (2023)
Myelofibrosis (MF) is a myeloproliferative neoplasm (MPN) with heterogeneous clinical course. Allogeneic hematopoietic cell transplantation remains the only curative therapy, but its morbidity and mortality require careful candidate selection. Theref
Externí odkaz:
https://doaj.org/article/b80233d27d284aceb361680826fa5bb8
Autor:
Álvaro Díaz-González, Elvira Mora, Gayane Avetisyan, Santiago Furió, Rosalía De la Puerta, José Vicente Gil, Alessandro Liquori, Eva Villamón, Carmen García-Hernández, Marta Santiago, Cristian García-Ruiz, Marta Llop, Blanca Ferrer-Lores, Eva Barragán, Silvia García-Palomares, Empar Mayordomo, Irene Luna, Ana Vicente, Lourdes Cordón, Leonor Senent, Alberto Álvarez-Larrán, José Cervera, Javier De la Rubia, Juan Carlos Hernández-Boluda, Esperanza Such
Publikováno v:
Cancers, Vol 15, Iss 11, p 3039 (2023)
Cytogenetic assessment in myelofibrosis is essential for risk stratification and patient management. However, an informative karyotype is unavailable in a significant proportion of patients. Optical genome mapping (OGM) is a promising technique that
Externí odkaz:
https://doaj.org/article/fa5758d9140b48b5b6c6e6a95ce4868e
Autor:
Valentín Garcia-Gutiérrez, Alejandro Luna, Juan M. Alonso-Dominguez, Natalia Estrada, Concepcion Boque, Blanca Xicoy, Pilar Giraldo, Anna Angona, Alberto Alvarez-Larrán, Fermin Sanchez-Guijo, María José Ramírez, Elvira Mora, Patricia Vélez, Ana Rosell, Mercedes Colorado Araujo, Beatriz Cuevas, Miguel Sagüés, Montserrat Cortes, Manuel Perez Encinas, Luis Felipe Casado Montero, Melania Moreno Vega, Luis Serrano, Valle Gomez, Carmen Garcia-Hernandez, Sunil Lakhwani, Antonio Paz Coll, Raquel de Paz, Sara Suarez-Varela, Andrés Fernandez-Ruiz, Raul Perez Lopez, Almudena Ortiz-Fernández, Antonio Jiménez-Velasco, Juan Luis Steegmann-Olmedillas, Juan Carlos Hernández-Boluda
Publikováno v:
Blood Cancer Journal, Vol 11, Iss 2, Pp 1-4 (2021)
Externí odkaz:
https://doaj.org/article/717b8583ea22422db39b5f3e0735ac0c
Autor:
Lucía Pérez-Lamas, Alejandro Luna, Concepción Boque, Blanca Xicoy, Pilar Giraldo, Raúl Pérez López, Concepción Ruiz Nuño, Natalia De las Heras, Elvira Mora Casterá, Javier López Marín, Adrián Segura Díaz, Valle Gómez, Patricia Vélez Tenza, Magdalena Sierra Pacho, Juan Antonio Vera Goñi, Melania Moreno Vega, Alberto Alvarez-Larrán, Montse Cortés, Manuel Pérez Encinas, Patricia Carrascosa Mastell, Anna Angona, Ana Rosell, Sunil Lakhwani, Mercedes Colorado, Elena Ramila, Carlos Cervero, Beatriz Cuevas, Lucía Villalón Blanco, Raquel de Paz, Antonio Paz Coll, María José Fernández, Luis Felipe Casado, Juan Manuel Alonso-Domínguez, María Magdalena Anguita Arance, Araceli Salamanca Cuenca, Antonio Jiménez-Velasco, Santiago Osorio Prendes, Marta Santaliestra, María José Lis Chulvi, Juan Carlos Hernández-Boluda, Valentín García-Gutiérrez
Publikováno v:
Cancers, Vol 15, Iss 4, p 1045 (2023)
(1) Background: Despite the prognostic improvements achieved with tyrosine kinase inhibitors (TKIs) in chronic myeloid leukemia (CML), a minority of patients still fail TKIs. The recent introduction of asciminib may be a promising option in intoleran
Externí odkaz:
https://doaj.org/article/8dcc0b35ed67421d85b66b3963e07cb1